Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C15H21N3O · 2H3PO4
CAS Number:
Molecular Weight:
455.34
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
3812133
grade
pharmaceutical primary standard
API family
primaquine
manufacturer/tradename
USP
mp
205-206 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
OP(O)(O)=O.OP(O)(O)=O.COc1cc(NC(C)CCCN)c2ncccc2c1
InChI
1S/C15H21N3O.2H3O4P/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14;2*1-5(2,3)4/h4,6,8-11,18H,3,5,7,16H2,1-2H3;2*(H3,1,2,3,4)
InChI key
GJOHLWZHWQUKAU-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Primaquine phosphate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monograph such as Primaquine Phosphate Tablets.
Also, for use with USP monograph such as Primaquine Phosphate Tablets.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Primaquine phosphate
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Muta. 2 - Repr. 2
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Improving the radical cure of Plasmodium vivax malaria.
Ric N Price
The American journal of tropical medicine and hygiene, 91(1), 3-4 (2014-04-23)
Tamar E Carter et al.
The American journal of tropical medicine and hygiene, 91(2), 412-414 (2014-06-04)
Haiti is one of two remaining malaria-endemic countries in the Caribbean. To decrease malaria transmission in Haiti, primaquine was recently added to the malaria treatment public health policy. One limitation of primaquine is that, at certain doses, primaquine can cause
N P Dhammika Nanayakkara et al.
Antimicrobial agents and chemotherapy, 58(8), 4737-4744 (2014-06-11)
Hematotoxicity in individuals genetically deficient in glucose-6-phosphate dehydrogenase (G6PD) activity is the major limitation of primaquine (PQ), the only antimalarial drug in clinical use for treatment of relapsing Plasmodium vivax malaria. PQ is currently clinically used in its racemic form.